INOVIO PHARMACEUTICALS, INC.

Listed Company

INOCIK 0001055726NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$65.3K

Net Income

$-84.90M

Total Assets

$74.31M

Equity

$24.10M

Shares Out

82.27M

Op. Cash Flow

$-88.63M

INO$1.12−18.61% · past yearDBEQ Basic

Daily closing prices

Business

Inovio Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines—optimized DNA plasmids delivered via proprietary electroporation devices—to treat HPV-associated diseases, cancers, and infectious diseases. Its lead candidate INO-3107 targets recurrent respiratory papillomatosis; other programs address oropharyngeal squamous cell carcinoma, glioblastoma, cervical precancers, and infectious diseases including COVID-19, Ebola, and HIV. The company has no approved products and generates revenue from licensing and milestone payments and collaborative research agreements.

Summary from 10-K filed 2026-03-12

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue from collaborative arrangement	65,343	217,756	832,010	10	2
Research and development	54	76	87	188	249
General and administrative	33	37	48	90	54
Total operating expenses	87	113	145	278	303
Loss from operations	−87	−112	−144	−268	−301
Interest income	2	5	8	—	—
Interest expense	0	−177,833	−1	—	—
Change in fair value of common stock warrant liabilities	493,231	3	0	—	—
Gain (loss) on investment in affiliated entity	489,844	−1	773,145	−2	−553,570
Net unrealized gain on available-for-sale equity securities	1	2	6	−8	−3
Other expense, net	−3	−3	−5	−4	343,371
Net loss	−85	−107	−135	−280	−304
Basic (in USD per share)	−1.81	−3.95	−6.09	−14.07	−17.45
Diluted (in USD per share)	−1.81	−3.95	−6.09	−14.07	−17.45
Basic (in shares)	47	27	22	20	17
Diluted (in shares)	47	27	22	20	17

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	44	66	14	46	71
Short-term investments	14	28	131	207	330
Prepaid expenses and other current assets, including from affiliated entity	3	4	5	50	39
Total current assets	61	98	153	315	448
Fixed assets, net	3	4	5	8	17
Investments in affiliated entity	2	2	3	2	4
Operating lease right-of-use assets	7	8	9	10	12
Other assets	2	2	605,315	684,044	1
Total assets	74	113	171	349	496
Accrued clinical trial expenses	650,680	2	2	11	10
Common stock warrant liabilities	29	13	0	—	—
Operating lease liability	3	2	2	3	3
Total current liabilities	44	35	43	97	66
Operating lease liability, net of current portion	7	9	11	13	15
Total liabilities	50	45	54	126	96
Commitments and contingencies	—	—	—	—	—
Preferred stockpar value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December 31, 2025 and 2024	0	0	0	0	0
Common stockpar value $0.001; Authorized shares: 600,000,000 at December 31, 2024 and 2023, issued and outstanding: 36,099,991 at December 31, 2024 and 22,793,075 at December 31, 2023	68,997	36,099	22,792	21,090	217,382
Additional paid-in capital	1,840	1,799	1,741	1,711	1,610
Accumulated deficit	−1,800	−1,730	−1,623	−1,488	−1,210
Accumulated other comprehensive loss	−637,963	−675,667	−662,601	−698,741	−282,236
Total Inovio Pharmaceuticals, Inc. stockholders equity	24	69	117	222	400
Total liabilities and stockholders equity	74	113	171	349	496

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	1	2	3	4	3
Amortization of operating lease right-of-use assets	2	1	736,472	1	1
Non-cash stock-based compensation	4	7	11	23	26
Non-cash interest on senior convertible notes	0	−355,654	155,814	186,977	858,644
Amortization of discounts on investments	−2,399	−2	−5	−1	2
Loss on sales of short-term investments	890,916	2	5	4	5,397
Net gain on disposal of fixed assets	0	−22,466	317,997	1	0
Prepaid expenses and other current assets, including from affiliated entity	1	3	39	−5	−6
Other assets	−32,821	38,900	78,729	741,750	25
Accounts payable and accrued expenses, including due to affiliated entity	−6	−3	−46	33	26
Accrued clinical trial expenses	−1	−343,522	−8	267,807	375,921
Operating lease right-of-use assets and liabilities, net	−2	−2	−2	−3	−2
Net cash used in operating activities	−89	−104	−124	−216	−216
Purchases of investments	−5	−54	−203	−249	−349
Proceeds from sale of investments	14	28	285	361	175
Proceeds from maturity of investments	5	131	—	—	—
Purchases of capital assets	−285,698	−487,832	−320,898	−969,153	−1
Proceeds from sale of capital assets	0	59,319	6	0	0
Net cash provided by investing activities	14	104	87	110	−175
Repayment of convertible senior notes	0	−16	0	—	—
Proceeds from issuance of common stock, net of issuance costs	35	36	5	83	209
Proceeds from warrant exercises	1	0	—	—	—
Proceeds from stock option exercises	1,000	68,000	0	—	—
Taxes paid related to net share settlement of equity awards	−110,783	−420,795	−466,646	−1	−5
Net cash provided by financing activities	53	51	5	82	211
Effect of exchange rate changes on cash and cash equivalents	0	32,403	−3,920	−25,556	−30,134
(Decrease) Increase in cash and cash equivalents	−22	52	−32	−25	−180
Interest paid	0	533,487	1	1	1

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is INOVIO PHARMACEUTICALS, INC.'s CIK number?

INOVIO PHARMACEUTICALS, INC.'s SEC CIK number is 0001055726 (1055726). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find INOVIO PHARMACEUTICALS, INC.'s SEC filings?

All of INOVIO PHARMACEUTICALS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did INOVIO PHARMACEUTICALS, INC. last report earnings?

INOVIO PHARMACEUTICALS, INC. (INO) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001055726-26-000019). This is INOVIO PHARMACEUTICALS, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is INOVIO PHARMACEUTICALS, INC.'s most recent earnings 8-K?

INOVIO PHARMACEUTICALS, INC.'s latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001055726-26-000019. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View INOVIO PHARMACEUTICALS, INC.'s latest earnings 8-K →
Look up any company's CIK number →